ClinConnect ClinConnect Logo
Search / Trial NCT04409561

Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population

Launched by ABIONIC SA · May 27, 2020

Trial Information

Current as of June 07, 2025

Completed

Keywords

Sepsis Pancreatic Stone Protein Immunoassay Abionic Healthy Population Point Of Care Device

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Male or female, aged ≥ 18 years.
  • 2. Apparently healthy as determined by a subject questionnaire.
  • Exclusion Criteria:
  • 1) Current diagnosis, or history, of any underlying major medical condition determined by the investigator, including but not limited to:
  • 1. Heart disease
  • 2. Stroke
  • 3. Renal disease
  • 4. Liver disease
  • 5. Pancreatic disease
  • 6. Chronic obstructive pulmonary disorder
  • 7. Bleeding disorders
  • 8. Hypercalcitoninemia
  • 9. HIV AIDS
  • 10. Receiving antibiotic therapy
  • 11. Suspected infection
  • 12. Immunosuppression
  • 2) Underwent procedures related to sepsis, or diagnosed with sepsis, within the last 12 months.
  • 3) Current diagnosis of uncontrolled hypertension, hypotension, or diabetes.
  • 4) Diagnosis of bacterial, fungal, or malaria infection within the last 3 months that required antimicrobial treatment.
  • 5 )Experienced severe trauma, surgery, cardiac shock, or severe burn within the previous 3 months requiring medical care.
  • 6) Current diagnosis of cancer within the last 12 months.
  • 7) Received immunotherapy to stimulate or inhibit cytokines within the last 12 months.
  • 8) Hospitalization for more than 24 hours within the last 3 months.
  • 9) Reported as currently pregnant or nursing a child
  • 10) Unable or unwilling to provide the required blood sample for testing.
  • 11) Any other criteria that, in the opinion of the investigator, would render the participant unsuitable for inclusion in the trial.

About Abionic Sa

Abionic SA is an innovative biotechnology company specializing in the development of rapid diagnostic tests that leverage advanced nanotechnology to improve patient care. Headquartered in Switzerland, Abionic focuses on creating efficient and cost-effective solutions for the early detection of critical health conditions, enabling timely medical interventions. With a commitment to enhancing diagnostic accuracy and accessibility, the company aims to transform the landscape of point-of-care testing, ultimately contributing to better health outcomes worldwide. Through rigorous clinical trials and collaborations, Abionic is dedicated to advancing its pioneering technologies in the healthcare sector.

Locations

Toledo, Ohio, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials